Compare · IDXX vs VRAX
IDXX vs VRAX
Side-by-side comparison of IDEXX Laboratories Inc. (IDXX) and Virax Biolabs Group Limited (VRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IDXX and VRAX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- IDXX is the larger of the two at $52.84B, about 33295.4x VRAX ($1.6M).
- IDXX has been more active in the news (10 items in the past 4 weeks vs 3 for VRAX).
- IDXX has more recent analyst coverage (25 ratings vs 1 for VRAX).
- Company
- IDEXX Laboratories Inc.
- Virax Biolabs Group Limited
- Price
- -
- -
- Market cap
- $52.84B
- $1.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1991
- 2022
- News (4w)
- 10
- 3
- Recent ratings
- 25
- 1
IDEXX Laboratories Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, and individual consumers. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. The company was incorporated in 2021 and is based in London, the United Kingdom.
Latest IDXX
- EVP, GC & Corporate Secretary Underberg Sharon E. exercised 8,906 shares at a strike of $288.78 and sold $6,132,605 worth of shares (8,906 units at $688.59) (SEC Form 4)
- Executive Vice President Lane Michael sold $2,740,069 worth of shares (3,979 units at $688.64), decreasing direct ownership by 49% to 4,076 units (SEC Form 4)
- Executive Chair of the Board Mazelsky Jonathan Jay exercised 25,140 shares at a strike of $178.26 and sold $17,678,195 worth of shares (25,140 units at $703.19) (SEC Form 4)
- Director Junius Daniel M sold $844,888 worth of shares (1,200 units at $704.07), decreasing direct ownership by 34% to 2,361 units (SEC Form 4)
- Director Hooley Joseph L was granted 48 shares, increasing direct ownership by 15% to 373 units (SEC Form 4)
- SEC Form 10-Q filed by IDEXX Laboratories Inc.
- IDEXX Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IDEXX Laboratories Announces Third Quarter Results
- Goldman initiated coverage on IDEXX Labs with a new price target
- KeyBanc Capital Markets initiated coverage on IDEXX Labs
Latest VRAX
- SEC Form 6-K filed by Virax Biolabs Group Limited
- Virax Biolabs Appoints Three Distributors for ImmuneSelect Research Products in Mainland China
- SEC Form 3 filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 424B5 filed by Virax Biolabs Group Limited
- SEC Form EFFECT filed by Virax Biolabs Group Limited
- Amendment: SEC Form F-3/A filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited
- SEC Form 6-K filed by Virax Biolabs Group Limited